<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03599778</url>
  </required_header>
  <id_info>
    <org_study_id>AHTH-201</org_study_id>
    <nct_id>NCT03599778</nct_id>
  </id_info>
  <brief_title>XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma</brief_title>
  <official_title>A Phase I/II Clinical Study to Compare Postoperative Chemotherapy of Oxaliplatin With Capecitabine（XELOX）Combined With APATINIB as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anhui Provincial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe and evaluate the efficacy and safety of oxaliplatin with&#xD;
      oapecitabine（XELOX）combined with apatinib as post-operative chemotherapy in locally advanced&#xD;
      gastric adenocarcinoma with D2 dissection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stage 1 (phase I tolerance study) : 12 patients were enrolled in the dose-climbing&#xD;
      study:According to the principle of dose-climbing test,todetermine the subjects' MTD, with&#xD;
      the following three dose levels:&#xD;
&#xD;
        -  Capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w) + apatinib 250&#xD;
           mg, qd x180d; ②. Capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w)&#xD;
           + apatinib 375 mg, qd x180d; ③. Capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130&#xD;
           mg/m2 d1 q3w) + apatinib 500 mg, qd x180d;&#xD;
&#xD;
      Stage 2 (phase II exploratory study) :&#xD;
&#xD;
      ①.Test group: subjects received 8 cycles of postoperative XELOX regimen (capecitabine: 1000&#xD;
      mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w) + apatinib maximum tolerated dose&#xD;
&#xD;
      ②.Control group: Subjects received 8 cycles of XELOX regimen after surgery (capecitabine:&#xD;
      1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w).&#xD;
&#xD;
      Eligible patients will receive 8 cycles of postoperative adjuvant therapy and will be&#xD;
      followed up to death&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2018</start_date>
  <completion_date type="Anticipated">January 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>3 months</time_frame>
    <description>Disease-free survival (DFS) is defined as the time from the beginning of treatment to Disease recurrence or death due to Disease progression</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Gastric Carcinoma</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w) + apatinib'MTD(maximum tolerated dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>XELOX + apatinib's MTD</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>treatment group</arm_group_label>
    <other_name>XELOX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ECOG score is 0-1;&#xD;
&#xD;
          2. Radical gastrectomy (D2, R0) for gastric cancer has been performed (more than 16 lymph&#xD;
             nodes have been detected);&#xD;
&#xD;
          3. Postoperative histology confirmed gastric adenocarcinoma；&#xD;
&#xD;
          4. The pathological stage of gastric cancer is ⅢA-ⅢC stage (8th AJCC TNM);&#xD;
&#xD;
          5. Subjects' baseline blood routine and biochemical indicators meet the following&#xD;
             standards:&#xD;
&#xD;
               -  ANC≥1.5×109/L;&#xD;
&#xD;
               -  Hb≥90g/L;&#xD;
&#xD;
               -  PLT≥100×109/L;&#xD;
&#xD;
               -  TBIL≤1.5×ULN;&#xD;
&#xD;
               -  ALT and AST≤2×ULN;&#xD;
&#xD;
               -  Cr≤1.5×ULN&#xD;
&#xD;
               -  INR：1.0～1.5; APTT is within the normal range&#xD;
&#xD;
          6. The electrocardiogram was basically normal before the first 4 weeks after admission,&#xD;
             and there were no obvious clinical symptoms of heart disease;&#xD;
&#xD;
          7. Sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with severe hypertension and poor drug control;&#xD;
&#xD;
          2. Various factors that affect oral drugs such as (inability to swallow, complete or&#xD;
             incomplete gastrointestinal obstruction, active gastrointestinal bleeding, perforation&#xD;
             ) ;&#xD;
&#xD;
          3. Patients with previous bradycardia or prolonged QT interval;&#xD;
&#xD;
          4. Patients with postoperative gastrointestinal fistula and wound rupture;&#xD;
&#xD;
          5. Known allergy to capecitabine or oxaliplatin, or metabolic disorder;&#xD;
&#xD;
          6. Patients receiving preoperative chemotherapy, radiotherapy or targeted therapy before;&#xD;
&#xD;
          7. Patients Using other experimental drugs at the same time or joining in other clinical&#xD;
             trials.&#xD;
&#xD;
          8. Patients with severe liver diseases (such as liver cirrhosis), nephropathy,&#xD;
             respiratory diseases or chronic systemic diseases such as uncontrollable diabetes and&#xD;
             hypertension; Clinical symptoms of heart disease,such as congestive heart&#xD;
             failure,coronary heart disease symptoms, arrhythmia, hypertension,that hard to&#xD;
             control,or having myocardial infarction attack in six months or cardiac insufficiency.&#xD;
&#xD;
          9. Patients with peripheral nervous system disorder or with a history of significant&#xD;
             psychiatric disorder and central nervous system disorder;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xinyang He, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anhui Provincial Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinyang He, master</last_name>
    <phone>13505518319</phone>
    <email>HXY2333@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Provincial Cancer Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 24, 2018</last_update_submitted>
  <last_update_submitted_qc>July 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>apatinib</keyword>
  <keyword>Gastric Carcinoma</keyword>
  <keyword>post-operative chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

